|  Download for Citation Managers
ORIGINAL ARTICLE
A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Prabhash Kumar, Doval D C, Rangarajan Bharath, Somani Naresh, Pruthi Aarohan, Dyachkova Yulia, Puri Tarun
Year : 2021 | Volume: 4 | Issue Number: 4 | Page: 634-641
Click here to read this article
|
| |
|
